1. Home
  2. GOSS vs CYPH Comparison

GOSS vs CYPH Comparison

Compare GOSS & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$0.15

Market Cap

83.8M

Sector

Health Care

ML Signal

HOLD

CYPH

Cypherpunk Technologies Inc.

HOLD

Current Price

$0.73

Market Cap

73.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
CYPH
Founded
2015
2011
Country
United States
United States
Employees
N/A
6
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.8M
73.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
GOSS
CYPH
Price
$0.15
$0.73
Analyst Decision
Buy
Analyst Count
8
0
Target Price
$4.19
N/A
AVG Volume (30 Days)
17.1M
2.2M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,471,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$201.64
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.49
52 Week High
$3.87
$3.70

Technical Indicators

Market Signals
Indicator
GOSS
CYPH
Relative Strength Index (RSI) 41.43 50.03
Support Level $0.15 $0.58
Resistance Level $0.20 $0.80
Average True Range (ATR) 0.02 0.06
MACD 0.00 0.02
Stochastic Oscillator 43.60 66.32

Price Performance

Historical Comparison
GOSS
CYPH

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

Share on Social Networks: